Company AnGes, Inc.

Equities

4563

JP3127700007

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Sales per region

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-04-26 am EDT			5-day change	1st Jan Change
49 ^JPY	0.00%		-2.00%	-31.94%

Jan. 19	Eiger BioPharmaceuticals Gets Marketing Approval for Treatment of Ultra-Rare Genetic Disease	MT
Jan. 18	Eiger BioPharmaceuticals, Inc. and Partner, AnGes, Inc. Receive Approval for Zokinvy for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan	CI

AnGes, Inc., formerly AnGes MG, Inc., is a Japan-based company mainly engaged in the development of genetic medicines. The Company is involved in the development of hepatocyte growth factor (HGF) genetic medicines, NF-KB decoy oligo and hemagglutinating virus of Japan envelope (HVJ-E) non-viral vector, among others. As of December 31, 2012, the Company had four consolidated subsidiaries. On January 31, 2013, the Company sold a 95.3% stake of a Osaka-based subsidiary to ISHIHARA SANGYO KAISHA LTD.

JPY in Million	2022	Weight	2023	Weight	Delta
Pharmaceutical 100.0 %	12	100.0 %	23	100.0 %	+100.12%

JPY in Million	2022	Weight	2023	Weight	Delta
Japan 100.0 %	12	100.0 %	23	100.0 %	+100.12%

Managers	Title	Age	Since
Tetsuji Yoneo DFI	Director of Finance/CFO	54	12-09-30
Ei Yamada PSD	President	73	01-04-30
Kazuo Suzuki CTO	Chief Tech/Sci/R&D Officer	67	19-01-31
Hajime Watanabe CTO	Chief Tech/Sci/R&D Officer	-	-
Jun Sakurai IRC	Investor Relations Contact	-	-

Members of the board	Title	Age	Since
Ei Yamada PSD	President	73	01-04-30
Makoto Hara BRD	Director/Board Member	73	18-03-28
Junichi Komamura BRD	Director/Board Member	73	12-02-29
Tetsuji Yoneo DFI	Director of Finance/CFO	54	12-09-30
Norikazu Eiki BRD	Director/Board Member	76	14-04-30
Kazuo Suzuki CTO	Chief Tech/Sci/R&D Officer	67	19-01-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	0	217,673,816	210,865,224 ( 96.87 %)	92 ( 0.000042 %)	96.87 %

Name	Equities	%	Valuation
Yuichiro Hayashi 0.6162 %	1,240,000	0.6162 %	540 752 ¥
SHIONOGI & CO., LTD. 0.5898 %	1,186,800	0.5898 %	517 552 ¥
Hiroshi Kawai 0.5164 %	1,039,100	0.5164 %	453 141 ¥
Ryuichi Morishita 0.3437 %	691,600	0.3437 %	301 600 ¥
Toshimi Otsuki 0.3230 %	650,000	0.3230 %	283 459 ¥
SPARX Asset Management Co., Ltd. 0.0235 %	47,300	0.0235 %	20 627 ¥
Dimensional Fund Advisors Ltd. 0.0102 %	20,487	0.0102 %	8 934 ¥
Sumitomo Mitsui Trust Asset Management Co., Ltd. 0.001758 %	3,538	0.001758 %	1 543 ¥
Sumitomo Mitsui Asset Management Co., Ltd. 0.001524 %	3,067	0.001524 %	1 337 ¥
Nykredit Bank A/S (Investment Management) 0.000745 %	1,500	0.000745 %	654 ¥

Name	Equities	%	Valuation
FUNPEP COMPANY LIMITED 0.77%	200,000	0.77%	231,260 $
FRESH TRACKS THERAPEUTICS, INC. 0.11%	6,535	0.11%	5,914 $

AnGes, Inc.

Saito Bio-Incubator, 1/F 7-7-15 Saito-Asagi

567-0085, Osaka

http://www.anges.co.jp

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
ANGES, INC.	-31.94%	62.66M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs